Trials that use: Log-rank test
New to this method? Read the tutorial →
459 results
- VA NEPHRON-DComplete statistical analysis of VA NEPHRON-D, a randomized phase 3 trial evaluating combination ARB and ACEI therapy versus ARB monotherapy in patients with diabetic nephropathy, including time-to-event endpoints, hazard ratios, confidence intervals,…
- VAST-DComplete statistical analysis of VAST-D, the phase 3 randomized trial of switching to bupropion-SR versus augmentation with bupropion-SR or aripiprazole for major depressive disorder, including remission, response, relapse, statistical methodology, safety, and…
- VELIAIndependent statistical analysis of the VELIA phase 3 trial of veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage III or IV high-grade serous epithelial…
- VENICEComplete statistical analysis of the phase 3 VENICE trial of aflibercept plus docetaxel in metastatic androgen independent prostate cancer, including randomized trial design, overall survival, hazard ratio interpretation, and time-to-event methodology.
- VERONICAIndependent statistical analysis of the VERONICA phase 2 trial comparing venetoclax plus fulvestrant with fulvestrant in women with ER-positive, HER2-negative locally advanced or metastatic breast cancer after CDK4/6 inhibitor therapy.
- VERTIS CVIndependent statistical analysis of VERTIS CV (NCT01986881): a stratified Cox non-inferiority analysis of ertugliflozin versus placebo for MACE with a 1.3 hazard-ratio margin, cLDA analyses of A1C change in glycemic sub-studies, secondary…
- VOYAGER PADA detailed independent statistical analysis of VOYAGER PAD, the randomized phase 3 trial of rivaroxaban plus aspirin versus placebo plus aspirin in symptomatic peripheral artery disease undergoing lower-extremity peripheral revascularization.
- YES-PIndependent statistical analysis of Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- ZENITHIndependent statistical analysis of A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH): primary endpoint results, effect estimate with confidence interval,…